Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus

OBJECTIVE: To investigate the long‐term safety and efficacy of intravenous (IV) belimumab plus standard of care (SOC) therapy for systemic lupus erythematosus (SLE) in patients with active, autoantibody‐positive SLE. METHODS: The study was designed as a multicenter, open‐label, continuation study of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wallace, Daniel J., Ginzler, Ellen M., Merrill, Joan T., Furie, Richard A., Stohl, William, Chatham, W. Winn, Weinstein, Arthur, McKay, James D., McCune, W. Joseph, Petri, Michelle, Fettiplace, James, Roth, David A., Ji, Beulah, Heath, Amy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Systemic Lupus Erythematosus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617785/
https://www.ncbi.nlm.nih.gov/pubmed/30771238
http://dx.doi.org/10.1002/art.40861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617785/
https://www.ncbi.nlm.nih.gov/pubmed/30771238
http://dx.doi.org/10.1002/art.40861

Ejemplares similares